The European Commission (EC) has approved a new method to administer Tysabri (natalizumab) as a treatment for people with…
Articles by Marisa Wexler, MS
People who develop multiple sclerosis (MS) as children are more likely to attain lower education levels, earn less in…
Treatment with the antioxidant N‐acetyl cysteine is well-tolerated, but failed to outperform a placebo at easing fatigue in people with…
A machine learning-based method that examines walking abnormalities in people with multiple sclerosis (MS) could help identify patients who…
The U.S. Food and Drug Administration (FDA) has authorized the use of a medical device called Portable Neuromodulation Stimulator or…
Injecting rituximab — a cancer therapy sometimes used in multiple sclerosis — into the spinal canal of people with progressive…
People with multiple sclerosis (MS) who have more extensive mobility issues are more likely to have worse outcomes from…
The U.S. Food and Drug Administration (FDA) has approved Ponvory (ponesimod) as an oral treatment for adults with relapsing…
In recognition of National Multiple Sclerosis (MS) Awareness Month — celebrated throughout March — Novartis and iHeartRadio are…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
People with multiple sclerosis (MS) who smoke tobacco or are not physically active are more likely to experience fatigue…
Two global Phase 3 clinical trials testing the investigational oral medication evobrutinib are recruiting participants with relapsing forms of…
People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta…
The Scottish Medicines Consortium (SMC) has approved Zeposia (ozanimod) for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Zeposia is…
A novel medication targeting the protein folate receptor-beta (FR-beta) decreased inflammation and brain damage in a rat model of…
The U.S. Food and Drug Administration (FDA) has approved an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat people…
A branch of the European Medicines Agency (EMA) has recommended that Kesimpta (ofatumumab) be approved and made available to treat…
Levels of neurofilament light (NfL), a protein marker of neuronal damage, appear to capture some aspects of patient‐perceived physical and…
Oleic acid, a type of fatty acid, is important for the function of immune cells that are dysregulated in…
Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the…
Helius Medical Technologies has submitted its response to the U.S. Food and Drug Administration (FDA)’s request…
To fully understand autoimmune diseases like multiple sclerosis (MS), it is necessary to study not just the immune system,…
The Multiple Sclerosis Association of America (MSAA) is hosting a webinar in which experts will discuss the COVID-19 pandemic…